Purple Biotech Ltd. (PPBT) shareholders
Close on Nov 13, 2026Market cap $1.52MP/E 0.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%) | 206,941,858 | 9.99% | 13G (passive) amendment | Sep 30, 2026 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 200,453,695 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 139,632,475 | 9.99% | 13G (passive) | Sep 4, 2025 |
| Susquehanna Securities, LLC | 93,953,400 | 5.20% | 13G (passive) | Dec 31, 2025 |
| Lincoln Alternative Strategies LLC | 605,000 | 9.90% | 13G (passive) | Sep 4, 2025 |
| Orca Capital AG | 605,000 | 9.90% | 13G (passive) | Sep 4, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (8.69%) | 223,000 | 8.69% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PPBT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| SmartHarvest Portfolios, LLC | 28,468 | 0.00% | $47.83K | +10,341 | 0.02% |
| Hrt Financial LP | 14,640 | 0.00% | $24.00K | New | 0.00% |
| Citadel Advisors LLC | 13,166 | 0.00% | $22.12K | New | 0.00% |
| Susquehanna International Group, Llp | 12,847 | 0.00% | $21.58K | −40,556 | 0.00% |
| Independent Advisor Alliance | 11,901 | 0.00% | $19.99K | New | 0.00% |
| SRS Capital Advisors, Inc. | 1,453 | 0.00% | $2.44K | New | 0.00% |
| Rhumbline Advisers | 856 | 0.00% | $1.44K | +146 | 0.00% |
| UBS Group AG | 751 | 0.00% | $1.26K | +652 | 0.00% |
| Morgan Stanley | 197 | 0.00% | $331 | −381 | 0.00% |
| Royal Bank of Canada | 128 | 0.00% | $0 | +118 | 0.00% |
| Northwestern Mutual Wealth Management Co | 8 | 0.00% | $13 | – | 0.00% |
| IFG Advisory, LLC | 7 | 0.00% | $12 | New | 0.00% |
| SBI Securities Co., Ltd. | 3 | 0.00% | $5 | −28 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 0.0% | 5 / 4 | 3 / 7 | 0M | 0M |
| Q1 2026 | 15 | 0M | 0.0% | 15 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1 funds held PPBT in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PPBT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | 10 | 0.00% | $17 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gil Efron | Chief Executive Officer | 15,750,000 | 0.85% | Mar 31, 2026 |
| Shai S. Lankry | Chief Financial Officer | 3,550,000 | 0.19% | Mar 30, 2026 |
| Michael Schickler | Head of Clinical & Reg Affairs | 9,254,472 | 0.50% | Mar 30, 2026 |
| Simcha Rock | Director | 3,207,690 | 0.17% | Apr 17, 2026 |
| Suzana Zilberberg | Director | 3,062,500 | 0.16% | Apr 7, 2026 |
| Ido Agmon | Director | 3,093,860 | 0.17% | Apr 6, 2026 |
| Robert E. Gagnon | Director | 3,062,500 | 0.16% | Mar 18, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Purple Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 363,124 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?